Evidence map›Paper›PMID 33948252›Full record

ArticleJournal of clinical and translational science2020

Integrating data science into the translational science research spectrum: A substance use disorder case study.

Emily Slade, Linda P Dwoskin, Guo-Qiang Zhang, Jeffery C Talbert, Jin Chen, Patricia R Freeman, Kathleen M Kantak, Emily R Hankosky, Sajjad Fouladvand, Amy L Meadows and 1 more

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emily SladeDepartment of Biostatistics, University of Kentucky, Lexington, KY, USA.ORCID https://orcid.org/0000-0002-1654-3822
Linda P DwoskinDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA.
Guo-Qiang ZhangUniversity of Texas Health Science Center at Houston, Houston, TX, USA.
Jeffery C TalbertInstitute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA.
Jin ChenInstitute for Biomedical Informatics, University of Kentucky, Lexington, KY, USA.
Patricia R FreemanInstitute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA.
Kathleen M KantakDepartment of Psychological and Brain Sciences, Boston University, Boston, MA, USA.
Emily R HankoskyDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA.
Sajjad FouladvandInstitute for Biomedical Informatics, University of Kentucky, Lexington, KY, USA.
Amy L MeadowsDepartment of Psychiatry, University of Kentucky, Lexington, KY, USA.
Heather M BushDepartment of Biostatistics, University of Kentucky, Lexington, KY, USA.

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Big Data to Treatment: Repurposing pharmacotherapies for psychostimulant use disorderF32DA045483 · NIDA · UNIVERSITY OF KENTUCKY · PI HANKOSKY, EMILY RUTH · 2018 to 2018
$65k
NCATS NIH HHS UL1 TR001998NIDA NIH HHS F32 DA045483
6 · The paper itself

Abstract

The availability of large healthcare datasets offers the opportunity for researchers to navigate the traditional clinical and translational science research stages in a nonlinear manner. In particular, data scientists can harness the power of large healthcare datasets to bridge from preclinical discoveries (T0) directly to assessing population-level health impact (T4). A successful bridge from T0 to T4 does not bypass the other stages entirely; rather, effective team science makes a direct progression from T0 to T4 impactful by incorporating the perspectives of researchers from every stage of the clinical and translational science research spectrum. In this exemplar, we demonstrate how effective team science overcame challenges and, ultimately, ensured success when a diverse team of researchers worked together, using healthcare big data to test population-level substance use disorder (SUD) hypotheses generated from preclinical rodent studies. This project, called Advancing Substance use disorder Knowledge using Big Data (ASK Big Data), highlights the critical roles that data science expertise and effective team science play in quickly translating preclinical research into public health impact.

Indexed as

Data sciencehealthcare big datasubstance use disorderteam sciencetranslational science research spectrum

Identifiers

PMID33948252
PMCPMC8057445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.